Pharmacokinetics of cefaclor and initial therapeutical experience (author's transl)

Twelve normal volunteers in the fasting state were given 1000 mg cefaclor, and the serum and urine concentrations over 8 h and 24 h respectively were measured. The average peak serum concentration was 34.6 +/- 7.8 mg/l, this value being reached after 65.2 +/- 11.1 min; the half-life was 42.5 +/- 8.3...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Infection 1979, Vol.7 Suppl 6, p.600
Hauptverfasser: Lode, H, Köppe, P, Stahlmann, R
Format: Artikel
Sprache:ger
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page 600
container_title Infection
container_volume 7 Suppl 6
creator Lode, H
Köppe, P
Stahlmann, R
description Twelve normal volunteers in the fasting state were given 1000 mg cefaclor, and the serum and urine concentrations over 8 h and 24 h respectively were measured. The average peak serum concentration was 34.6 +/- 7.8 mg/l, this value being reached after 65.2 +/- 11.1 min; the half-life was 42.5 +/- 8.3 min. In another six volunteers the absorption of 500 mg of 'cefaclor following administration in the fasting state and after a test breakfast was studied. The peak serum concentrations after administration in the fasting state were 16.1 +/- 3.2 mg/l, and after a meal 12.5 +/- 1.9 mg/l; the areas under the curve did not differ. The low recovery rate of cefaclor in urine observed in this series of investigations could be partly explained by the inactivation of the substance in urine. Cefaclor was administered therapeutically to 23 patients, most of whom were suffering from bronchopulmonary infections and chronic pyelonephritis. The results of therapy were good in four patients, satisfactory in 13 patients and unsatisfactory in three patients. Intolerance was rare.
format Article
fullrecord <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_551086</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>551086</sourcerecordid><originalsourceid>FETCH-LOGICAL-g456-cfaa911433766f1ff8499cd42e7689cd422e5e7aecaa49998c98c64d1e9dc7543</originalsourceid><addsrcrecordid>eNotT0tLxDAYzMHXuvoPPOSmHgpJm0dzlMUXLCi49-Xz6xcbbdOStKD_3uIKAzPDDANzxFaiEqKoZWnO2HnOn0II7ZQ9ZSdaS1GbFXt7bSH1gMNXiDQFzHzwHMkDdkPiEBseYpgCdHxqKcFI81JaHH2PlAJFJH4D89QO6TrzKUHM3e0FO_bQZbr85zXbPdzvNk_F9uXxeXO3LT6UNgV6ACelqiprjJfe18o5bFRJ1tR_oiRNFggBlsTVuMCoRpJr0GpVrdnVYXac33tq9mMKPaSf_eFa9Qu6Lkqj</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Pharmacokinetics of cefaclor and initial therapeutical experience (author's transl)</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Lode, H ; Köppe, P ; Stahlmann, R</creator><creatorcontrib>Lode, H ; Köppe, P ; Stahlmann, R</creatorcontrib><description>Twelve normal volunteers in the fasting state were given 1000 mg cefaclor, and the serum and urine concentrations over 8 h and 24 h respectively were measured. The average peak serum concentration was 34.6 +/- 7.8 mg/l, this value being reached after 65.2 +/- 11.1 min; the half-life was 42.5 +/- 8.3 min. In another six volunteers the absorption of 500 mg of 'cefaclor following administration in the fasting state and after a test breakfast was studied. The peak serum concentrations after administration in the fasting state were 16.1 +/- 3.2 mg/l, and after a meal 12.5 +/- 1.9 mg/l; the areas under the curve did not differ. The low recovery rate of cefaclor in urine observed in this series of investigations could be partly explained by the inactivation of the substance in urine. Cefaclor was administered therapeutically to 23 patients, most of whom were suffering from bronchopulmonary infections and chronic pyelonephritis. The results of therapy were good in four patients, satisfactory in 13 patients and unsatisfactory in three patients. Intolerance was rare.</description><identifier>ISSN: 0300-8126</identifier><identifier>PMID: 551086</identifier><language>ger</language><publisher>Germany</publisher><subject>Cefaclor - blood ; Cefaclor - metabolism ; Cefaclor - urine ; Cephalexin - analogs &amp; derivatives ; Fasting ; Female ; Humans ; Male ; Pyelonephritis - drug therapy ; Pyelonephritis - metabolism ; Respiratory Tract Infections - drug therapy ; Respiratory Tract Infections - metabolism ; Time Factors</subject><ispartof>Infection, 1979, Vol.7 Suppl 6, p.600</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/551086$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lode, H</creatorcontrib><creatorcontrib>Köppe, P</creatorcontrib><creatorcontrib>Stahlmann, R</creatorcontrib><title>Pharmacokinetics of cefaclor and initial therapeutical experience (author's transl)</title><title>Infection</title><addtitle>Infection</addtitle><description>Twelve normal volunteers in the fasting state were given 1000 mg cefaclor, and the serum and urine concentrations over 8 h and 24 h respectively were measured. The average peak serum concentration was 34.6 +/- 7.8 mg/l, this value being reached after 65.2 +/- 11.1 min; the half-life was 42.5 +/- 8.3 min. In another six volunteers the absorption of 500 mg of 'cefaclor following administration in the fasting state and after a test breakfast was studied. The peak serum concentrations after administration in the fasting state were 16.1 +/- 3.2 mg/l, and after a meal 12.5 +/- 1.9 mg/l; the areas under the curve did not differ. The low recovery rate of cefaclor in urine observed in this series of investigations could be partly explained by the inactivation of the substance in urine. Cefaclor was administered therapeutically to 23 patients, most of whom were suffering from bronchopulmonary infections and chronic pyelonephritis. The results of therapy were good in four patients, satisfactory in 13 patients and unsatisfactory in three patients. Intolerance was rare.</description><subject>Cefaclor - blood</subject><subject>Cefaclor - metabolism</subject><subject>Cefaclor - urine</subject><subject>Cephalexin - analogs &amp; derivatives</subject><subject>Fasting</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Pyelonephritis - drug therapy</subject><subject>Pyelonephritis - metabolism</subject><subject>Respiratory Tract Infections - drug therapy</subject><subject>Respiratory Tract Infections - metabolism</subject><subject>Time Factors</subject><issn>0300-8126</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1979</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNotT0tLxDAYzMHXuvoPPOSmHgpJm0dzlMUXLCi49-Xz6xcbbdOStKD_3uIKAzPDDANzxFaiEqKoZWnO2HnOn0II7ZQ9ZSdaS1GbFXt7bSH1gMNXiDQFzHzwHMkDdkPiEBseYpgCdHxqKcFI81JaHH2PlAJFJH4D89QO6TrzKUHM3e0FO_bQZbr85zXbPdzvNk_F9uXxeXO3LT6UNgV6ACelqiprjJfe18o5bFRJ1tR_oiRNFggBlsTVuMCoRpJr0GpVrdnVYXac33tq9mMKPaSf_eFa9Qu6Lkqj</recordid><startdate>1979</startdate><enddate>1979</enddate><creator>Lode, H</creator><creator>Köppe, P</creator><creator>Stahlmann, R</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>1979</creationdate><title>Pharmacokinetics of cefaclor and initial therapeutical experience (author's transl)</title><author>Lode, H ; Köppe, P ; Stahlmann, R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g456-cfaa911433766f1ff8499cd42e7689cd422e5e7aecaa49998c98c64d1e9dc7543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>ger</language><creationdate>1979</creationdate><topic>Cefaclor - blood</topic><topic>Cefaclor - metabolism</topic><topic>Cefaclor - urine</topic><topic>Cephalexin - analogs &amp; derivatives</topic><topic>Fasting</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Pyelonephritis - drug therapy</topic><topic>Pyelonephritis - metabolism</topic><topic>Respiratory Tract Infections - drug therapy</topic><topic>Respiratory Tract Infections - metabolism</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lode, H</creatorcontrib><creatorcontrib>Köppe, P</creatorcontrib><creatorcontrib>Stahlmann, R</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Infection</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lode, H</au><au>Köppe, P</au><au>Stahlmann, R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacokinetics of cefaclor and initial therapeutical experience (author's transl)</atitle><jtitle>Infection</jtitle><addtitle>Infection</addtitle><date>1979</date><risdate>1979</risdate><volume>7 Suppl 6</volume><spage>600</spage><pages>600-</pages><issn>0300-8126</issn><abstract>Twelve normal volunteers in the fasting state were given 1000 mg cefaclor, and the serum and urine concentrations over 8 h and 24 h respectively were measured. The average peak serum concentration was 34.6 +/- 7.8 mg/l, this value being reached after 65.2 +/- 11.1 min; the half-life was 42.5 +/- 8.3 min. In another six volunteers the absorption of 500 mg of 'cefaclor following administration in the fasting state and after a test breakfast was studied. The peak serum concentrations after administration in the fasting state were 16.1 +/- 3.2 mg/l, and after a meal 12.5 +/- 1.9 mg/l; the areas under the curve did not differ. The low recovery rate of cefaclor in urine observed in this series of investigations could be partly explained by the inactivation of the substance in urine. Cefaclor was administered therapeutically to 23 patients, most of whom were suffering from bronchopulmonary infections and chronic pyelonephritis. The results of therapy were good in four patients, satisfactory in 13 patients and unsatisfactory in three patients. Intolerance was rare.</abstract><cop>Germany</cop><pmid>551086</pmid></addata></record>
fulltext fulltext
identifier ISSN: 0300-8126
ispartof Infection, 1979, Vol.7 Suppl 6, p.600
issn 0300-8126
language ger
recordid cdi_pubmed_primary_551086
source MEDLINE; SpringerNature Journals
subjects Cefaclor - blood
Cefaclor - metabolism
Cefaclor - urine
Cephalexin - analogs & derivatives
Fasting
Female
Humans
Male
Pyelonephritis - drug therapy
Pyelonephritis - metabolism
Respiratory Tract Infections - drug therapy
Respiratory Tract Infections - metabolism
Time Factors
title Pharmacokinetics of cefaclor and initial therapeutical experience (author's transl)
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T08%3A27%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacokinetics%20of%20cefaclor%20and%20initial%20therapeutical%20experience%20(author's%20transl)&rft.jtitle=Infection&rft.au=Lode,%20H&rft.date=1979&rft.volume=7%20Suppl%206&rft.spage=600&rft.pages=600-&rft.issn=0300-8126&rft_id=info:doi/&rft_dat=%3Cpubmed%3E551086%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/551086&rfr_iscdi=true